Literature DB >> 9585323

Clinical spectrum of botulism.

M Cherington1.   

Abstract

Botulism is a paralyzing disease caused by the toxin of Clostridium botulinum. The toxin produces skeletal muscle paralysis by producing a presynaptic blockade to the release of acetylcholine. Recent studies have pinpointed the site of action of the several types of botulinum neurotoxin at the nerve terminal. Since the discovery of the toxin about 100 years ago, five clinical forms of botulism have been described: 1) classic or foodborne botulism; 2) wound botulism; 3) infant botulism; 4) hidden botulism; 5) inadvertent botulism. A clinical pattern of descending weakness is characteristic of all five forms. Almost all human cases of botulism are caused by one of three serotypes (A, B, or E). Classic and wound botulism were the only two forms known until the last quarter of this century. Wound botulism was rare until the past decade. Now there are increasing numbers of cases of wound botulism in injecting drug users. Infant botulism, first described in 1976, is now the most frequently reported form. In infant botulism spores of Clostridium botulinum are ingested and germinate in the intestinal tract. Hidden botulism, the adult variant of infant botulism, occurs in adult patients who usually have an abnormality of the intestinal tract that allows colonization by Clostridium botulinum. Inadvertent botulism is the most recent form to be described. It occurs in patients who have been treated with injections of botulinum toxin for dystonic and other movement disorders. Laboratory proof of botulism is established with the detection of toxin in the patient's serum, stool, or wound. The detection of Clostridium botulinum bacteria in the stool or wound should also be considered evidence of clinical botulism. Electrophysiologic studies can provide presumptive of botulism in patients with the clinical signs of botulism. Electrophysiologic testing can be especially helpful when bioassay studies are negative. The most consistent electrophysiologic abnormality is a small evoked muscle action potential in response to a single supramaximal nerve stimulus in a clinically affected muscle. Posttetanic facilitation can be found in some affected muscles. Single-fiber EMG studies typically reveal increased jitter and blocking, which become less marked following activation. The major treatment for severe botulism is advance medical and nursing supportive care with special attention to respiratory status.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585323     DOI: 10.1002/(sici)1097-4598(199806)21:6<701::aid-mus1>3.0.co;2-b

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  35 in total

Review 1.  Uses of botulinum toxin injection in medicine today.

Authors:  A Münchau; K P Bhatia
Journal:  BMJ       Date:  2000-01-15

2.  Botulism in Canada.

Authors:  E Weir
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

3.  Treatment of two unusual cases of type A and E botulism following consumption of salted fish.

Authors:  P Vahdani; M R Pourshafie; Z Aminzadeh
Journal:  Intensive Care Med       Date:  2002-08       Impact factor: 17.440

Review 4.  Clostridial neurotoxins.

Authors:  A Goonetilleke; J B Harris
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

Review 5.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

6.  Clinically and electrophysiologically diagnosed botulinum intoxication.

Authors:  Dilcan Kotan; Recep Aygul; Mustafa Ceylan; Yalcin Yilikoglu
Journal:  BMJ Case Rep       Date:  2013-01-03

7.  Botulism-induced unilateral submandibular sialoadenitis: a case report.

Authors:  Sara Gasparini; Edoardo Ferlazzo; Giovanbattista Gaspare Tripodi; Vittoria Cianci; Umberto Aguglia
Journal:  Neurol Sci       Date:  2013-05-18       Impact factor: 3.307

Review 8.  Botulinum neurotoxins: genetic, structural and mechanistic insights.

Authors:  Ornella Rossetto; Marco Pirazzini; Cesare Montecucco
Journal:  Nat Rev Microbiol       Date:  2014-06-30       Impact factor: 60.633

9.  Isolation and quantification of botulinum neurotoxin from complex matrices using the BoTest matrix assays.

Authors:  F Mark Dunning; Timothy M Piazza; Füsûn N Zeytin; Ward C Tucker
Journal:  J Vis Exp       Date:  2014-03-03       Impact factor: 1.355

Review 10.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.